Empathy, affection and sociability enhancement

From PsychonautWiki
Jump to: navigation, search

Empathy, affection, and sociability enhancement can be described as the experience of a mind state which is dominated by intense feelings of compassion,[1][2][3] talkativeness,[4] and happiness. The experience of this effect creates a wide range of subjective changes to a person's perception of their feelings towards other people and themselves. These are described and documented in the list below:

  • Increased sociability and the feeling that communication comes easier and more naturally.
  • Increased urge to communicate or express one's affectionate feelings towards others, even if they happen to be strangers.
  • Increased feelings of empathy,[4] love, and connection with others.
  • Increased motivation to resolve social conflicts and improve interpersonal relationships.
  • Decreased negative emotions and mental states such as stress, anxiety, and fear.
  • Decreased insecurity, defensiveness, and fear of emotional injury or rejection from others.
  • Decreased irritability, aggression, anger, and jealousy.

Empathy, affection, and sociability enhancement is often accompanied by other coinciding effects such as stimulation, personal bias suppression, motivation enhancement, and anxiety suppression. It is most commonly induced under the influence of moderate dosages of entactogenic compounds such as MDMA, 4-FA, and 2C-B. However, it can also subtly occur to a much lesser extent under the influence of GABAergic depressants, and certain stimulants.

Psychoactive substances

Compounds within our psychoactive substance index which may cause this effect include:

Experience reports

Anecdotal reports which describe this effect within our experience index include:

See also


  1. Tanaka, E., Kamata, T., Katagi, M., Tsuchihashi, H., & Honda, K. (2006). A fatal poisoning with 5-methoxy-N, N-diisopropyltryptamine, Foxy. Forensic science international, 163(1-2), 152-154. https://doi.org/10.1016/j.forsciint.2005.11.026
  2. Shulgin, A. T., & Carter, M. F. (1980). N, N-Diisopropyltryptamine (DIPT) and 5-methoxy-N, N-diisopropyltryptamine (5-MeO-DIPT). Two orally active tryptamine analogs with CNS activity. Communications in psychopharmacology, 4(5), 363-369. https://www.ncbi.nlm.nih.gov/pubmed/6949674
  3. Muller, A. A. (2004). New drugs of abuse update: Foxy Methoxy. Journal of Emergency Nursing, 30(5), 507-508. https://doi.org/10.1016/j.jen.2004.07.037
  4. 4.0 4.1 Meatherall, R., & Sharma, P. (2003). Foxy, a designer tryptamine hallucinogen. Journal of analytical toxicology, 27(5), 313-317. http://citeseerx.ist.psu.edu/viewdoc/download;jsessionid=F3773EF1876BD69CAF408DA77CCBF8EF?doi=